© 1991 by Oxford University Press
Journal of the National Cancer Institute, Vol. 83, No. 15, 1072-1077,
August 7, 1991
© 1991 Oxford University Press
Cancer Risk After Iodine-131 Therapy for Hyperthyroidism
Department of Cancer Prevention, Rediumhemmet, Karolinska Hospital Stockholm, Sweden
Department of General Oncology, Rediumhemmet, Karolinska Hospital Stockholm, Sweden
Department of Cancer Epidemiology, Rediumhemmet, Karolinska Hospital Stockholm, Sweden
Department of General Oncology, Sahlgren's Hospital Gothenburg, Sweden
Nuclear Medicine Division, Sahlgren's Hospital Gothenburg, Sweden
Department of General Oncology, Malmö General Hospital Malmö, Sweden
Department of Internal Medicine, Malmö General Hospital Malmö, Sweden
Department of General Oncology, University Hospital Lund, Sweden
Department of General Oncology, University Hospital Ume{acute}, Sweden
Department of Hospital Physics, South Hospital Stockholm, Sweden
Department of General Oncology, University Hospital Uppsala, Sweden
Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer Institute Bethesda, Md
*Correspondence to: Lars-Erk Holm, M.D., Department of Cancer Prevention, Radiumhemmet, Karolinska Hospital, S-10401 Stockholm, Sweden
Cancer incidence was studied in 10 552 patients (mean age, 57 years) who received 131I therapy (mean dose, 506 MBq) for hyperthyroidism between 1950 and 1975. Follow-up on these patients was continued for an average of 15 years. Record linkage with the Swedish Cancer Register for the period 1958–1985 identified 1543 cancers occurring 1 year or more after 131I treatment, and the standardized incidence ratio (SIR) was 1.06 (95% confidence interval = 1.01–1.11). Significantly increased SIRs were observed for cancers of the lung (SIR = 1.32; n = 105) and kidney (SIR = 1.39; n = 66). Among 10-year survivors, significantly elevated risks were seen for cancers of the stomach (SIR = 1.33; n = 58), kidney (SIR = 1.51; n = 37), and brain (SIR = 1.63; n = 30). Only the risk for stomach cancer, however, increased over time (P<.05) and with increasing activity administered (P = not significant). The risk for malignant lymphoma was significantly below expectation (SIR = 0.53; n = 11). Overall cancer risk did not increase with administered 131I dose or with time since exposure. The absence of any increase in leukemia adds further support to the view that a radiation dose delivered gradually over time is less carcinogenic than the same total dose received over a short time. Only for stomach cancer was a possible radiogenic excess suggested. [J Natl Cancer Inst 83: 1072–1077, 1991]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Abraham-Nordling, S. Lonn, G. Wallin, L. Yin, O. Nyren, O. Tullgren, P. Hall, and O. Torring Hyperthyroidism and suicide: a retrospective cohort study in Sweden Eur. J. Endocrinol., March 1, 2009; 160(3): 437 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Zablotska, T. I. Bogdanova, E. Ron, O. V. Epstein, J. Robbins, I. A. Likhtarev, M. Hatch, V. V. Markov, A. C. Bouville, V. A. Olijnyk, et al. A Cohort Study of Thyroid Cancer and Other Thyroid Diseases after the Chornobyl Accident: Dose-Response Analysis of Thyroid Follicular Adenomas Detected during First Screening in Ukraine (1998-2000) Am. J. Epidemiol., February 1, 2008; 167(3): 305 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Metso, P. Jaatinen, H. Huhtala, A. Auvinen, H. Oksala, and J. Salmi Increased Cardiovascular and Cancer Mortality after Radioiodine Treatment for Hyperthyroidism J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2190 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Lee, M. M. Grumbach, and O. H. Clark The Optimal Treatment for Pediatric Graves' Disease Is Surgery J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 801 - 803. [Full Text] [PDF]
|
|
|
|
 |
|
 K Boelaert and J A Franklyn Thyroid hormone in health and disease J. Endocrinol., October 1, 2005; 187(1): 1 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-A. Nieuwlaat, A. R. Hermus, H. A. Ross, W. C. Buijs, M. A. Edelbroek, J. W. Bus, F. H. Corstens, and D. A. Huysmans Dosimetry of Radioiodine Therapy in Patients with Nodular Goiter After Pretreatment with a Single, Low Dose of Recombinant Human Thyroid-Stimulating Hormone J. Nucl. Med., April 1, 2004; 45(4): 626 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Faggiano, J. Coulot, N. Bellon, M. Talbot, B. Caillou, M. Ricard, J.-M. Bidart, and M. Schlumberger Age-Dependent Variation of Follicular Size and Expression of Iodine Transporters in Human Thyroid Tissue J. Nucl. Med., February 1, 2004; 45(2): 232 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jonsson and S. Mattsson Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism Radiat Prot Dosimetry, January 15, 2004; 108(2): 107 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Hermida, E. Tcheng, G. Jarry, V. Moullart, S. Arlot, J.-L. Rey, J. Delonca, and C. Schvartz Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias Europace, January 1, 2004; 6(2): 169 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Dillman Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma J. Clin. Oncol., August 15, 2002; 20(16): 3545 - 3557. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Biagi, R. G. MacKenzie, M. S. Lim, M. Sapp, and N. Berinstein Primary Hodgkin's disease of the CNS in an immunocompetent patient: A case study and review of the literature Neuro-oncol, October 1, 2000; 2(4): 239 - 243. [Abstract] [PDF]
|
|
|
|
 |
|
 K. A. Woeber Update on the Management of Hyperthyroidism and Hypothyroidism Arch Fam Med, August 1, 2000; 9(8): 743 - 747. [Full Text] [PDF]
|
|
|
|
 |
|
 M.J. Ramirez, S. Puerto, P. Galofre, E.M. Parry, J.M. Parry, A. Creus, R. Marcos, and J. Surralles Multicolour FISH detection of radioactive iodine-induced 17cen-p53 chromosomal breakage in buccal cells from therapeutically exposed patients Carcinogenesis, August 1, 2000; 21(8): 1581 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Woeber Update on the Management of Hyperthyroidism and Hypothyroidism Arch Intern Med, April 24, 2000; 160(8): 1067 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Rivkees, C. Sklar, and M. Freemark The Management of Graves' Disease in Children, with Special Emphasis on Radioiodine Treatment J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3767 - 3776. [Full Text]
|
|
|
|
 |
|
 E. Ron, M. M. Doody, D. V. Becker, A. B. Brill, R. E. Curtis, M. B. Goldman, B. S. H. Harris III, D. A. Hoffman, W. M. McConahey, H. R. Maxon, et al. Cancer Mortality Following Treatment for Adult Hyperthyroidism JAMA, July 22, 1998; 280(4): 347 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Hermus and D. A. Huysmans Treatment of Benign Nodular Thyroid Disease N. Engl. J. Med., May 14, 1998; 338(20): 1438 - 1447. [Full Text] [PDF]
|
|
|
|
|
|
J.A. Franklyn, P. Maisonneuve, M.C. Sheppard, J. Betteridge, and P. Boyle Mortality after the Treatment of Hyperthyroidism with Radioactive Iodine N. Engl. J. Med., March 12, 1998; 338(11): 712 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T D CHEETHAM, I A HUGHES, N D BARNES, and E P WRAIGHT Treatment of hyperthyroidism in young people Arch. Dis. Child., March 1, 1998; 78(3): 207 - 209. [Full Text]
|
|
|
|
|
|
J. D. Boice Jr, J. S. Mandel, and M. M. Doody Breast Cancer Among Radiologic Technologists JAMA, August 2, 1995; 274(5): 394 - 401. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Franklyn The Management of Hyperthyroidism N. Engl. J. Med., June 16, 1994; 330(24): 1731 - 1738. [Full Text]
|
|